Impact of CVVHD With Adsorption Capacity Membranes in Septic Acute Kidney Injury
Launched by HOSPITAL UNIVERSITARI DE BELLVITGE · Feb 12, 2013
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
Investigators will warrant a correct protocol application. Study data will be reviewed by an external monitoring committee from the clinical assay research central unit (UCICEC - IDIBELL). Monitors will contrast registered data from the collection data form (CDF) with data from patient´s medical record. All patient´s medical records will be indefinitely saved in electronical format to be reviewed if necessary.
Patients who meet inclusion criteria will be randomized for one of both arms with aleatory assignation using a randomisation sequential (RndSeq) program for Statistical Package for t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Less than 72 hours from ICU admission to inclusion
- • Clinical diagnosis of Severe Sepsis or Septic shock (SCCM definitions)
- • Correct therapeutic initial management of septic process (SSC guidelines)
- • Clinical diagnosis of Acute Kidney Injury (ADQI definitions)
- • Acute Kidney Injury meeting CRRT initiation criteria (ADQI guidelines)
- • Written informed consent from patient or legal surrogates
- Exclusion Criteria:
- • End Stage Renal Disease(ESRD)
- • Received previous CRRT or hemodialysis in the last three months
- • Inclusion in other ongoing study
- • Coexisting illness with a high probability of death
- • Immunosuppression
Trial Officials
Joan Sabater Riera, MD
Principal Investigator
Hospital Universitari de Bellvitge
Xosé L. Pérez Fernández, MD
Study Director
Hospital Universitari de Bellvitge
Antoni Betbesé Roig, MD
Study Director
Hospital de Sant Pau
Jorge Ordoñez Llanos, MD PhD
Study Chair
Hospital de Sant Pau
About Hospital Universitari De Bellvitge
Hospital Universitari de Bellvitge is a leading academic medical center located in L'Hospitalet de Llobregat, Spain, affiliated with the University of Barcelona. Renowned for its commitment to advanced patient care, innovative research, and education, the hospital plays a pivotal role in the development and execution of clinical trials across various therapeutic areas. With a multidisciplinary team of healthcare professionals and researchers, Hospital Universitari de Bellvitge strives to enhance medical knowledge and improve treatment outcomes through rigorous scientific inquiry and collaboration. Its state-of-the-art facilities and comprehensive patient care services make it an ideal environment for conducting high-quality clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
L'hospitalet De Llobregat, Barcelona, Spain
L'hospitalet De Llobregat, Barcelona, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials